Regulations.gov document
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics…
Notice · FDA-2022-D-0235 · posted Jun 17, 2024
Key facts
| Document ID | FDA-2022-D-0235-0010 |
|---|---|
| Title | Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2022-D-0235 |
| Posted | Jun 17, 2024 |
| Federal Register citation | 89 FR 51354 |
| FR document number | 2024-13271 |
| Comment period opens | Jun 17, 2024 |
| Effective date | Jun 17, 2024 |
At a glance
- 1–9 Pages
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: